NDAINJECTIONINJECTABLE
Approved
May 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OPTIRAY 350 (ioversol) by Guerbet is x-ray contrast activity [moa]. First approved in 1998.
Drug data last refreshed 4h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPTIRAY 350 (ioversol) is an injectable radiographic contrast agent used to enhance X-ray imaging during diagnostic procedures. It works through X-ray contrast activity to improve visualization of blood vessels and organs. This non-ionic, low-osmolarity contrast medium is administered intravenously for angiography, urography, and other radiological examinations.
LOE Approaching
As LOE approaches, the brand team is likely consolidating and shifting focus toward lifecycle extension or asset transition strategies.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
OPTIRAY 350 offers limited career growth opportunities due to its LOE-approaching lifecycle and lack of active job openings. Roles on this product are maintenance-focused, emphasizing managed care negotiation and market share defense rather than expansion.
Brand ManagerField Sales Representative
Worked on OPTIRAY 350 at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.